rLP2086

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Meningitis, Meningococcal, Serogroup B

Conditions

Meningitis, Meningococcal, Serogroup B

Trial Timeline

Feb 1, 2013 → Feb 1, 2014

NCT ID

NCT01768117

About rLP2086

rLP2086 is a phase 2 stage product being developed by Pfizer for Meningitis, Meningococcal, Serogroup B. The current trial status is completed. This product is registered under clinical trial identifier NCT01768117. Target conditions include Meningitis, Meningococcal, Serogroup B.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01352845	Phase 3	Completed	May 1, 2013	Feb 1, 2015	Healthy
NCT01768117	Phase 2	Completed	Feb 1, 2013	Feb 1, 2014	Meningitis, Meningococcal, Serogroup B

Competing Products

20 competing products in Meningitis, Meningococcal, Serogroup B

See all competitors

Product	Company	Stage	Hype Score
RotaTeq® + NeisVac-C®	Merck	Phase 3	77
Daptomycin	Merck	Pre-clinical	23
Meningococcal ACWY conjugate vaccine	Novartis	Phase 3	77
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine	Novartis	Approved	85
Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaP	Novartis	Phase 3	77
Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and Menveo	Novartis	Phase 3	77
Meningococcal ACWY conjugate vaccine	Novartis	Phase 3	77
MenACWY-CRM + MenC-CRM + DTaP-Hib-IPV + PC7 + MMR + Varicella	Novartis	Phase 2	52
Hib-CRM197 + Hib-TT	Novartis	Phase 3	77
Novartis Meningococcal ACWY Conjugate Vaccine + Tdap Vaccine + Novartis Meningococcal ACWY Conjugate Vaccine	Novartis	Phase 3	77
MenACWY-CRM conjugate vaccine, adjuvanted + MenACWY polysaccharide vaccine + MenACWY-CRM conjugate vaccine, unadjuvanted	Novartis	Phase 2	52
meningococcal B vaccine & meningococcal ACYW conjugate vaccine	Novartis	Phase 2	52
Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine	Novartis	Phase 2	52
4CMenB	Novartis	Approved	85
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine	Novartis	Phase 3	77
Meningococcal (group B) multicomponent recombinant adsorbed vaccine	Novartis	Phase 3	77
MenACWY-CRM197 (two doses) + MenC + PCV7 + DTPa-IPV-HepB-Hib + MenACWY-CRM197 (one dose)	Novartis	Phase 3	77
MenACWY-CRM197 + DTaP (Diptheria, Tetanus, Pertussis) Vaccine + Hib (Haemophilus influenza b) Vaccine + IPV (Inactivated Polio Vaccine) Vaccine + Pneumococcal conjugate Vaccine + MMR (Measles, Mumps, and Rubella) Vaccine + Varicella Vaccine + Hepatitis A Virus	Novartis	Phase 3	77
Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years)	Novartis	Phase 3	77
Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Control + Meningococcal B vaccine with antipyretic	Novartis	Phase 2	52

Other Products from Pfizer